Feature Story
A Cancer Trial’s Unexpected Result: Remission in Every Patient
SUNDAY, June 5 (The New York Times) — It was a small trial, just 18 rectal cancer patients, every one of whom took the same drug.
But the results were astonishing. The cancer vanished in every single patient, undetectable by physical exam, endoscopy, PET scans or M.R.I. scans.
Dr. Luis A. Diaz Jr. of Memorial Sloan Kettering Cancer Center, an author of a paper published Sunday in the New England Journal of Medicine describing the results, which were sponsored by the drug company GlaxoSmithKline, said he knew of no other study in which a treatment completely obliterated a cancer in every patient.
In other news. . .
How structural medical racism perpetuates Asian American cancer disparities
June 7, NBC News
Some cancer patients can skip radiation or chemo, 2 studies show
June 7, CBS News
Breast Cancer Drug Trial Results in ‘Unheard-Of’ Survival
June 7, The New York Times
Racial minorities have higher death rates from cancer than white patients, study shows
June 8, ABC News
Foundation News
Are your routine cancer screenings Back on the Books?
Due to the pandemic, we’ve seen two years of missed doctor appointments and medical screenings—including routine cancer screenings and vaccinations. One-half of Americans who had a scheduled in-person medical appointment or screening either missed, postponed or canceled one or more of these appointments. Our newly released screenings snapshot indicates what cancer screenings you should get at every age.
